share_log

NanoViricides to Present at the Global AMR Summit 2024 Tomorrow

NanoViricides to Present at the Global AMR Summit 2024 Tomorrow

nanoviricides將於明日在全球AMR峯會上發表演講
Accesswire ·  2024/10/08 18:30

Dr. Diwan to Discuss "Shape-Shifting", "Trojan Horse", Pathogen-Directed Attack Capability of NanoViricides Platform Technology to Combat AMR

Diwan博士將討論NanoViricides平台技術的"變形","特洛伊木馬",病原體定向攻擊能力來對抗AMR

SHELTON, CT / ACCESSWIRE / October 8, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, today announces that Anil R. Diwan, Ph.D., the Company's President and Executive Chairman, has been invited and will be presenting a talk at the Global AMR Summit, which is being held at the Kimpton Marlowe Hotel, Cambridge, MA, tomorrow, October 9, 2024.

康涅狄格州SHELTON / ACCESSWIRE / 2024年10月8日 / NanoViricides, Inc.(紐約證券交易所-美國:NNVC)("公司") ,一家臨床階段的全球領先者,致力於廣譜抗病毒納米醫藥,今天宣佈該公司總裁兼執行主席Anil R. Diwan博士受邀並將在全球抗微生物耐藥性峯會上發表演講。該峯會將於明天,2024年10月9日在馬薩諸塞州劍橋市的Kimpton Marlowe酒店舉行。

AMR, or "Anti-Microbial Resistance" leads to the failure of antibiotic therapy in bacteria, yeasts, fungi, and other human pathogens, as these pathogens have been evolving to escape the anti-microbial drugs developed against them.

抗微生物耐藥性(AMR)導致抗生素治療在細菌、酵母菌、真菌和其他人類病原體中的失敗,因爲這些病原體一直在進化以逃避對其開發的抗微生物藥物。

Dr. Diwan will present NanoViricides' "Trojan Horse" Platform Technology that enables delivery of one or more "war-heads" against a pathogen directly onto the pathogen, sparing normal host cells. This pathogen-directed therapy is expected to result in reduced toxicity and improved pharmacokinetics for the anti-microbial war-heads encapsulated within the nanoviricide micelle.

Diwan博士將介紹NanoViricides的"特洛伊木馬"平台技術,該技術可以將一個或多個"戰斧"直接投放到病原體上,避開正常宿主細胞。預計這種病原體定向療法將導致包含在nanoviricide膠束中的抗微生物戰斧的毒性降低和藥代動力學改善。

"The 'shape-shifting' nanoviricide platform technology opens up new avenues for combatting anti-microbial resistance," commented Dr. Diwan, adding, "We have already developed nanoviricide drugs against viruses that promise to combat the problem of viral escape from a drug. We believe this technology can be applied to develop novel anti-microbial drugs in order to solve the AMR problem."

"'變形'的nanoviricide平台技術爲打擊抗微生物耐藥性開闢了新途徑,"Diwan博士評論道","我們已經開發出針對病毒的nanoviricide藥物,有望解決病毒對藥物的逃逸問題。我們相信這項技術可以應用於開發新型抗微生物藥物以解決AMR問題。"

The global Antibiotic Resistance Market size was valued at USD 8.98 billion in 2022 and is poised to grow from USD 10.16 billion in 2023 to USD 27.39 billion by 2031, growing at a CAGR of 13.19% during the forecast period (2024-2031), according to a Skyquest Market Report ().

全球抗生素耐藥市場規模在2022年達到了898億美元,在2023年從1,016億美元增長到2031年的2,739億美元,預計在預測期間(2024-2031)以13.19%的年複合增長率增長,根據Skyquest市場報告。

The Company's lead drug, NV-387, a broad-spectrum host-mimetic antiviral, has successfully completed Phase 1a/1b human clinical trials in healthy subjects, with no reported adverse events, indicating excellent safety and tolerability.

該公司的主導藥物NV-387,一種廣譜模擬宿主抗病毒藥物,已成功完成了健康受試者的1a/10億臨床試驗,未報告任何不良事件,表明具有出色的安全性和耐受性。

The same drug NV-387 has demonstrated strong antiviral activity against viruses from multiple families, including Coronaviruses (SARS-CoV-2, Long COVID, Seasonal coronaviral infections), RSV, Influenza A, as well as a Smallpox/Mpox related mouse virus in stringent, lethal viral infection animal models. In all of these cases, NV-387 led to improvement in survival that substantially exceeded or was at least on par with that from already approved drugs or known antiviral agents.

同一藥物NV-387已經展示出對來自多個家族的病毒具有強大的抗病毒活性,包括冠狀病毒(SARS-CoV-2,長期COVID,季節性冠狀病毒感染),RSV,甲型流感,以及與天花/白天花相關的小鼠病毒,在嚴格、致命的病毒感染動物模型中。在所有這些情況下,NV-387都導致生存率的改善明顯超過或至少與已批准的藥物或已知抗病毒藥物相當。

The host-mimetic design of the nanoviricide NV-387 is expected to make escape of viruses from the drug highly unlikely, thus solving the major problem in development of antiviral countermeasures.

納米抗病毒劑NV-387的宿主模仿設計預計會使病毒逃逸藥物的可能性極小,從而解決了抗病毒對策開發中的主要問題。

NV-387 could be the very first single drug that can treat all of the "tripledemic" viral infections, namely, Coronaviruses, RSV, and Influenza A.

NV-387可能是全球首個可以治療所有「三重流行病」的單一藥物,即冠狀病毒、RSV和甲型流感。

In addition, the Company is also developing "dual-action" nanoviricides that promise to completely cure viral infections by virtue of attacking both the "Re-Infection" part as well as the "Replication" part, thus blocking the complete Virus Life Cycle, by exploiting the "shape-shifting", and "Trojan-Horse" capabilities of the nanoviricide technology platform.

此外,該公司還在開發「雙重作用」納米抗病毒劑,承諾通過攻擊「再感染」部分和「複製」部分完全治癒病毒感染,從而阻斷病毒完整生命週期,利用納米抗病毒技術平台的「變形」和「特洛伊木馬」能力。

About Global AMR Summit 2024: The Premier Forum for Antimicrobial Resistance and Global Public Health

關於全球抗菌耐藥機制峯會2024:抗菌耐藥和全球公共衛生的首要論壇

Welcome to the Global AMR Summit 2024, where global biotechnology and pharmaceutical companies will meet with leading experts and researchers in Boston, Massachusetts, to discuss the causes and response to antibiotic resistance and to understand the value of novel antibiotics to address the threat of AMR to public health.

歡迎參加全球抗菌耐藥機制峯會2024,全球生物技術和藥品公司將與波士頓馬薩諸塞州領先專家和研究人員會面,討論抗生素耐藥性的原因和應對措施,並了解新型抗生素在解決抗菌耐藥威脅公共衛生的價值。

Antimicrobial Resistance (AMR) is a serious and growing concern to global public health, with 1.5 million deaths annually. Due to the escalation of Antibiotic Resistance Pathogenic Bacteria (ARPB) and Multi-Drug Resistance (MDR) in pathogenic bacteria, public health is returning to the "pre-antibiotic era" because of the non-effectiveness of present antibiotics against bacterial infections. The lack of rapid diagnostics and poor infection prevention control has transformed AMR into a global public health threat.

抗菌耐藥性(AMR)是全球公共衛生面臨的嚴重且日益加劇的問題,每年有150萬人死亡。由於病原菌對抗生素的耐藥性和病原菌的多藥耐藥性不斷加劇,由於現有抗生素對細菌感染的不起作用,公共衛生正在重返「抗生素前時代」。快速診斷的缺乏和良好的感染預防控制已經將AMR轉變爲全球公共衛生威脅。

Next-generation antimicrobials and vaccines to combat the 'silent pandemic' of antimicrobial resistance are on the priority list of global healthcare. Embracing new technologies, such as disrupting protein folding, photodynamic therapy, antimicrobial peptides, and AI-based antibiotics, will help overcome the challenges of Antimicrobial Resistance.

全球衛生保健的重點之一是研發下一代抗微生物藥物和疫苗以應對抗微生物藥物的"潛在大流行"。採用新技術,如干擾蛋白質摺疊、光動力療法、抗微生物肽和基於人工智能的抗生素,將有助於克服抗微生物藥物的挑戰。

This year's Global AMR Summit will become the world's leading exhibition and conference exclusively for pharmaceutical and biotechnology companies to address scientific and business solutions in next-generation antimicrobials and vaccines to combat antimicrobial resistance.

今年的全球抗微生物藥物耐藥性高峰會將成爲全球領先的展覽會和會議,專門針對製藥和生物技術公司,解決下一代抗微生物藥物和疫苗以應對抗微生物藥物耐藥性的科學和業務解決方案。

This event will provide a forum for global pharmaceutical and biotechnology stakeholders to network and build cross-market relationships to explore new technologies and technical know-how to address the challenges in antimicrobial and antimicrobial resistance.

本次活動將爲全球製藥和生物技術利益相關者提供一個論壇,以建立跨市場關係,探討新技術和技術知識,以解決抗微生物藥物和抗微生物藥物耐藥性方面的挑戰。

About NanoViricides

關於NanoViricides

NanoViricides, Inc. (the "Company") () is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide class of drug candidates and the nanoviricide technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

nanoviricides公司是一家臨床階段公司,正在爲抗病毒治療創造特殊用途的納米材料。該公司的新型納米病毒滅活劑候選藥物和納米病毒技術基於TheraCour Pharma公司的知識產權、技術和專有技術。該公司與TheraCour簽署了一份關於基於這些技術開發抗所有抗病毒感染藥物的諒解備忘錄。該諒解備忘錄不包括可能源於病毒但需要不同治療方式的癌症和類似疾病。

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

公司已從TheraCour Pharma,Inc.獲得了廣泛的、獨家的、可轉讓的領域許可,涵蓋了幾個許可領域內開發的藥物。公司的商業模式是基於從TheraCour Pharma,Inc.獲得特定病毒應用垂直領域的技術許可,自2005年成立以來已確立。

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

我們的首席藥物候選是NV-387,一種廣譜抗病毒藥物,我們計劃將其開發爲RSV、COVID、長期COVID、流感以及其他呼吸道病毒感染的治療,以及MPOX/天花感染。我們的另一種先進藥物候選是用於帶狀皰疹治療的NV-HHV-1。公司無法預測任何藥物提出IND申請的確切日期,因爲依賴於許多外部合作伙伴和顧問。公司目前專注於將NV-387推進至第II期人體臨床試驗。

NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

NV-CoV-2(API NV-387)是我們的針對COVID-19的納米病毒滅活劑候選藥物,不包含瑞德西韋。NV-CoV-2-R是我們的另一種針對COVID-19的藥物候選藥物,由封裝在其聚合物膠囊中的NV-387和瑞德西韋組成。公司認爲,由於瑞德西韋已經獲得美國FDA批准,我們封裝瑞德西韋的藥物候選者很可能是一種可批准的藥物,如果安全性相當。瑞德西韋由吉利德開發。公司獨立研發了兩種藥物候選者NV-CoV-2和NV-CoV-2-R。

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

本公司還在開發針對多種病毒性疾病的藥物,包括口腔和生殖器皰疹,眼部病毒性疾病,包括流行性角結膜炎和皰疹性角膜炎,H1N1甲型流感,H5N1禽流感,季節性流感,艾滋病病毒,丙型肝炎,狂犬病,登革熱和埃博拉病毒等。 NanoViricides的平台技術和項目基於TheraCour的納米藥物技術,TheraCour從AllExcel獲得許可。 NanoViricides擁有這項技術的全球獨家永久許可證,用於針對以下多種人類病毒性疾病的具體靶向機制一直有效的特定藥物治療:人類免疫缺陷病毒(HIV / AIDS),乙型肝炎病毒(HBV),臨床研究和需求繁重。與任何公司的任何藥物開發努力一樣,目前無法保證本公司的任何藥物候選者是否顯示出足夠的有效性和安全性進行人類臨床開發。此外,目前無法保證我們在實驗室抗冠狀病毒的成功結果將導致成功的臨床試驗或成功的藥品。

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

本新聞稿包含反映公司目前關於未來事件的期望的前瞻性語句。實際事件可能會大大不同於本文所述,並取決於許多因素。NanoViricides,Inc.的某些聲明,以及其他書面或口頭聲明都是「前瞻性語句」,其含義在1933年證券法第27A節和1934年證券交易法第21E節中。由於它們涉及已知和未知的風險,不確定性和其他因素,因此您不應過分依賴前瞻性語句,並且這些因素在某些情況下超出了公司的控制並且可能會很可能,實質性地影響實際結果,活動水平,性能或成就。公司不承擔公開更新或修正這些前瞻性語句的義務,出於任何原因,或更新原因實際結果可能與這些前瞻性語句中所預期的結果不同,即使將來出現新信息。導致實際結果與公司預期有所不同的重要因素包括但不限於那些文件中披露的「風險因素」和其他監管機構的公司從時間到時間提交的其他文件中披露的那些因素。雖然不可能預測或識別所有這些因素,但它們可能包括以下因素:在臨床前試驗中演示和原則證明納米病毒滅活劑是安全和有效的;成功開發我們的產品候選品;我們能否尋求並獲得監管批准,包括我們正在尋求的適應症;我們產品候選品的成功商業化;以及我們的產品市場接受度。

The phrases "safety", "effectiveness" and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

本新聞稿中使用的「安全性」,「有效性」及其等效短語指研究發現,包括臨床試驗,作爲慣常的研究用途,其不表示由美國FDA評估的安全性或有效性。

FDA refers to US Food and Drug Administration. IND application refers to "Investigational New Drug" application. cGMP refers to current Good Manufacturing Practices. CMC refers to "Chemistry, Manufacture, and Controls". CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for "Active Pharmaceutical Ingredient". WHO is the World Health Organization. R&D refers to Research and Development.

FDA是美國食品藥品監督管理局。IND申請指的是「新藥臨床試驗申請」。cGMP是指當前良好生產規範。CMC指的是「化學、生產和質量控制」。CHMP是指負責人類藥品的歐洲藥品管理局(EMA)委員會。API代表「原料藥」。WHO是世界衛生組織。研發指的是研究與開發。

Contact:


聯繫方式:

NanoViricides, Inc., info@nanoviricides.com

納米病毒公司,info@nanoviricides.com

Public Relations Contact: ir@nanoviricides.com

公共關係聯繫人:ir@nanoviricides.com

SOURCE: NanoViricides, Inc.

消息來源:NanoViricides,Inc。


声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論